Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 710.50M | -2.35B | 672.49M | -80.03M | 860.22M |
| Total Depreciation and Amortization | 1.02B | 773.16M | 1.24B | 1.25B | 1.26B |
| Total Amortization of Deferred Charges | -- | 271.12M | -- | -- | -- |
| Total Other Non-Cash Items | 206.85M | 179.26M | 767.64M | 1.24B | -392.96M |
| Change in Net Operating Assets | -1.14B | 1.60B | -255.21M | 148.76M | -233.34M |
| Cash from Operations | 801.05M | 474.94M | 2.42B | 2.56B | 1.49B |
| Capital Expenditure | -337.76M | -295.45M | -270.14M | -271.88M | -331.74M |
| Sale of Property, Plant, and Equipment | 6.88M | 344.10K | 97.30K | 0.00 | 44.21M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 65.67M | 3.28M | 20.54M | 2.40M | 202.80M |
| Other Investing Activities | -285.28M | -77.90M | -1.24B | -56.91M | -145.09M |
| Cash from Investing | -550.49M | -369.72M | -1.49B | -326.39M | -229.82M |
| Total Debt Issued | -- | 60.00B | 0.00 | 342.51B | 183.56B |
| Total Debt Repaid | -11.29B | -85.62B | -9.89B | -305.95B | -183.53B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1.01B | 0.00 | 0.00 | 0.00 | -51.60B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -942.33M | -56.00M | -967.03M | -59.58M | -1.01B |
| Other Financing Activities | -17.92B | -43.09B | -33.53B | -39.75B | -18.02B |
| Cash from Financing | -1.13B | -493.82M | -1.25B | -81.24M | -1.49B |
| Foreign Exchange rate Adjustments | 39.89M | 7.00M | 145.63M | 90.62M | -16.86M |
| Miscellaneous Cash Flow Adjustments | 6.30K | -6.40K | -- | -- | -- |
| Net Change in Cash | -841.53M | -381.61M | -172.27M | 2.25B | -243.06M |